Differentiating WFS1 (wolframin mutation), usually presenting with diabetes mellitus and optic atrophy, from WFS2 (CISD2 mutation), often associated with additional gastrointestinal ulceration and bleeding, remains important in guiding counseling and prognosis. This evidence concerns the gene CISD2 and optic atrophy.